Expert Interview
Discussing the standard of care and the potential of Qulipta (Atogepant), a once-daily oral drug initially approved in 2021 for preventing episodic migraines in adult patients that just got an expanded label to treat chronic migraines.
Ticker(s): ABBVInstitution: Lovelace Neurosciences
- Neurologist in Albuquerque, NM
- Currently manages 800 patients with migraine
- Familiar with the ith the results from the Phase 3 MOMENTUM and INTERCEPT trials trial of AXS-07
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
